Pembrolizumab is a humanized antibody used in cancer immunotherapy. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells, and allows the immune system to destroy those cancer cells. It targets the programmed cell death 1 (PD-1) receptor of lymphocytes. The FDA initially approved it to treat metastatic melanoma.
中文别名:
派姆单抗; 帕博利珠单抗
英文别名:
Keytruda; Lambrolizumab; Lanbrolizumab; MK 3475; Merck 3475